A Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
Key facts
- Who runs it
- Tuberculosis Research Centre, India
- Where
- India15 sites in 1 countryChoose a country to see its sites
- Trial code
- NCT07947056
- CTRI/2026/02/102698
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 2,500 people, planned
- Started
- 6 Jun 2026
- Expected to end
- Dec 2029
- Type of study
- Interventional, 4 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Standard 6-month treatment regimen
- High dose Rifampicin (25mg/Kg)
- High dose Rifamipicn (25mg/Kg) & Levofloxacin
- Record updated
- 18 November 2026
Who can take part
- Age
- 14 years to 70 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Individuals aged equal or above 14 years
- Symptomatic persons with newly diagnosed sputum positive PTB - smear or NAAT should be positive for Mtb
- Re treatment patients who had previous one episode of microbiologically confirmed (by smear and /or NAAT) pulmonary TB and currently symptomatic and sensitive to all first line anti-TB drugs and quinolones
- If HIV +ve, CD4> 150 cells/mm3 and willing to take ART if not already on it with stable viremia
- Willing to follow the trial procedures
Who cannot take part
- Patients with h/o of concomitant medications which may interfere with study drugs
- Anti-TB treatment, >14 days for the current illness
- HIV Patients on second line ART regimens
- Baseline Hepatic or renal disease as evidenced by clinical or biochemical abnormalities; ALT/AST> 2.5 times ULN withTotal bilirubin >2 mg/dl or isolated ALT/AST >5 times ULN (Hy's law criteria); Serum Creatinine >1.2 mg/dl
- Body weight less than 30 kg in adults
- Known Resistance to rifampicin \& Isoniazid at baseline as evidenced by Nucleic acid Amplification test (NAAT) OR LPA
- Patients with serious forms of Extra-pulmonary TB
- Pregnant or lactating mothers
- Patients who are seriously ill including symptoms like pneumothorax or hemoptysis with hemodynamic instability
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 14 and 70 years old?
This trial is currently available in India.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
This multi-centric RCT across 15 sites in India, tries to evaluates two strategies in order to improve treatment outcomes and reduce recurrences among persons with drug sensitive pulmonary TB (i) Usage of High dose Rifampicin (25mg/kg) given either for 2 months or for 6 months along with other first line anti-TB drugs (ii) Addition of a Fluoroquinolone along with high dose rifampicin to reduce the treatment duration from 6 months to 4 months.
The 4 groups in the trial
- 2H R25 ZE /4 H R10 ETreatment being tested
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily conventional dose of Rifampicin(10mg), Isoniazid, and Ethambutol
Treatment: High dose Rifampicin (25mg/Kg)
- 2 H R25 ZE/ 4 H R25 ETreatment being tested
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, and Ethambutol Continuation Phase: Four months of daily treatment with high dose Rifampicin (25mg/kg), Isoniazid, and Ethambutol
Treatment: High dose Rifampicin (25mg/Kg)
- 2 H R25 ZE L/2 H R25 E LTreatment being tested
Intensive Phase: Two months of daily treatment with High dose Rifampicin (25mg/kg), isoniazid, pyrazinamide, Ethambutol and Levofloxacin (750/1000mg) Continuation Phase: Two months of daily high dose Rifampicin (25mg/kg), Isoniazid, Ethambutol and Levofloxacin.
Treatment: High dose Rifamipicn (25mg/Kg) & Levofloxacin
- 2 H R10 ZE /4H R10 EExisting treatment, for comparison
Intensive Phase: Two months of daily Rifampicin, Isoniazid, Pyrazinamide and Ethambutol Continuation Phase: Four months of Rifampicin, Isoniazid, and Ethambutol
Treatment: Standard 6-month treatment regimen
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multi-Centric Parallel Arm Randomized Controlled Clinical Trial to Improve Treatment Outcomes Among Persons With Drug Sensitive Pulmonary TB Treated With 4 or 6 Months of High Dose Rifampicin Containing Regimens With or Without Levofloxacin
- Criteria questions
- Built from NCT07947056, who can take part
- Record updated
- 18 November 2026